tbuckley/cabot-search huggingface dataset:
Psychosocial correlates of sleep architecture in women with advanced breast cancer.
Authors: Arianna Aldridge Gerry, Booil Jo, Oxana Palesh, Jamie Zeitzer, Eric Neri, David Spiegel
Journal: Journal of Clinical Oncology (2012)

9051 Background: Sleep disturbance is prevalent among metastatic breast cancer (MBC) patients and few studies have objectively evaluated this problem using polysomnography (PSG). Disturbed sleep negatively affects quality of life. The current study examines the relationship of mood and family structure with sleep parameters assessed over three nights of PSG (2 at-home, 1 in-lab). Methods: MBC patients (n = 103) and healthy controls (n = 27) were recruited. Patients were 57.8 years (SD = 7.7), non-Hispanic white (86.3%), and had Karnofsky ratings of at least 70%. Multiple regression analyses assessed relationships among depression, cohabitation, and sleep parameters. Results: Among patients, sleep architecture was significantly related to depression and marital status/cohabitation. Women reporting more depressive symptoms had less deep sleep: lower percentage (B = -.26, p = .01) and fewer minutes of REM (B = -.23, p = .02), lower % (B = -.25, p = .02) and fewer minutes of stage 2 sleep (B = -.28, p = .01), and more % stage 1 sleep (B = .28, p = .01). Marriage/cohabitation was positively related to sleep quality indicators: less wake time after sleep onset (B = -.20, p = .05), better sleep efficiency (B = .28, p = .01), more total sleep time (B = .30, p &lt; .01), more minutes of REM (B = .23, p = .02), more stage 2 sleep (B = .27, p &lt; .01), and less % stage 1 sleep (B = -.27, p = .01). Relative to healthy women, patients had more sleep stage transitions/hour (B = .21, p = .03), more awakenings (B = .18, p = .04), and more time awake after sleep onset (B = .21, p = .02). Slow wave (deep, non-REM) sleep was shorter for patients as measured by both minutes (B = -.20, p = .04) and % of stage 4 sleep (B = -.23, p = .02). Conclusions: Depressed patients or those living alone have greater reductions in deep sleep. Relative to healthy women, patients’ sleep disturbance and quality was worse. These findings demonstrate that the architecture of deep sleep is linked to depression and family structure.
Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients
Authors: Preetesh Jain, Hagop M. Kantarjian, Elias J. Jabbour, Graciela Nogueras Gonzalez, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna, Keyur P. Patel, Shimin Hu, Sara Emogene DellaSala, Sherry Pierce, Koji Sasaki, Marina Konopleva, William G. Wierda, Naval Daver, Tapan M. Kadia, Gautam Borthakur, Zeev Estrov, Farhad Ravandi, Susan M. O'Brien, Jorge E. Cortes
Journal: Blood (2016)
COMPARISON OF DIFFERENT LUNG ULTRASOUND METHODOLOGIES FOR PULMONARY CONGESTION EVALUATION IN HEART FAILURE OUTPATIENTS
Authors: Jose Plutarco Gutierrez Yanez, Luna Gargani, Eugenio Picano, Tiago Leiria, Renato Kalil, Roberto Santanna, Vitor Martins, Marciane Rover, Rosa Sicari, Marcelo Miglioranza
Journal: Journal of the American College of Cardiology (2017)
Heart Failure in Pediatric Patients With Congenital Heart Disease
Authors: Robert B. Hinton, Stephanie M. Ware
Journal: Circulation Research (2017)

Heart failure (HF) is a complex clinical syndrome resulting from diverse primary and secondary causes and shared pathways of disease progression, correlating with substantial mortality, morbidity, and cost. HF in children is most commonly attributable to coexistent congenital heart disease, with different risks depending on the specific type of malformation. Current management and therapy for HF in children are extrapolated from treatment approaches in adults. This review discusses the causes, epidemiology, and manifestations of HF in children with congenital heart disease and presents the clinical, genetic, and molecular characteristics that are similar or distinct from adult HF. The objective of this review is to provide a framework for understanding rapidly increasing genetic and molecular information in the challenging context of detailed phenotyping. We review clinical and translational research studies of HF in congenital heart disease including at the genome, transcriptome, and epigenetic levels. Unresolved issues and directions for future study are presented.
Clinical and Laboratory Validation of the 2nd International Standard of Low Molecular Weight Heparin (IS 2003-01/608) in the Anti-Xa, Anti-LIA Heptest and Prothrombinase Induced Clotting (PiCT) Tests.
Authors: D. Hoppensteadt, W. Jeske, D. Fareed, F. Baltasar, J. M. Walenga, M. Tobu, M. Demir, O. Iqbal, R. Wahi, J. Fareed
Journal: Blood (2005)
ASSOCIATION BETWEEN CD4+ LYMPHOCYTE COUNT AND LEFT VENTRICULAR DIASTOLIC FUNCTION AND GEOMETRY IN NEWLY DIAGNOSED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) NAIVE HIV/AIDS PATIENTS SEEN AT UNIVERSITY OF PORT HARCOURT TEACHING HOSPITAL, PORT HARCOURT, RIVERS STATE
Authors: Abaram Chesa Mankwe, Osaretan J. Odia
Journal: Journal of the American College of Cardiology (2017)
IMPLANTABLE CARDIOVERTER DEFIBRILLATORS FOR THE PREVENTION OF MORTALITY IN PATIENTS WITH NON-ISCHEMIC CARDIOMYOPATHY: A META-ANALYSIS OF RANDOMIZED CONTROL TRIALS
Authors: Wally A. Omar, Akhil Parashar, Rohan Khera, Ambarish Pandey
Journal: Journal of the American College of Cardiology (2017)
Outcomes of patients with advanced cancer and <i>KRAS</i> mutation in phase I clinical trials.
Authors: Apostolia Maria Tsimberidou, Rabih Said, Gerald Steven Falchook, Filip Janku, Aung Naing, Ralph Zinner, George R. Blumenschein, Siqing Fu, David S. Hong, Sarina Anne Piha-Paul, Jennifer J. Wheler, Yang Ye, Kenneth R. Hess, Gary A. Palmer, Robert A. Wolff, Razelle Kurzrock
Journal: Journal of Clinical Oncology (2013)

e22086 Background: The prognostic significance of KRAS mutations varies by mutation type. We compared the outcomes of patients with different KRASmutations treated in phase I clinical trials. Methods: Patients with advanced cancer and KRAS mutation who were treated in the phase I program from 9/08 to 12/12 were analyzed. The presence and type of KRAS mutation in the patients’ tumor samples were assessed in a CLIA-certified laboratory using PCR, sequenom analysis or next-generation sequencing. We compared clinical outcomes according to type of mutation, tumor, and therapy. Results: KRAS mutations were identified in 365 patients (codon 12, n=278; codon 13, n = 49; other codon, n = 38). The median age was 59 yrs (range, 18-87); and 46% men. Of 365 patients, 260 had KRAS mutation alone; 105 patients had 130 additional aberrations: PI3KCA, n=45 (39%); p53, n=29 (25.2%); PTEN, n=22 (19%); other, n=34 (29%). Of 260 patients, 159 were treated and evaluable for response. Outcomes in patients with KRAS mutation alone or with KRAS and additional molecular aberrations are shown in the Table. Conclusions: Keeping in mind that the number of patients was small, our results demonstrate heterogeneity in outcomes of patients with KRAS mutations. Combination studies of MEK inhibitors with other drugs may have improved antitumor activity. [Table: see text]
The Different Treatment Approaches in Younger Patients with Angioimmunoblastic T-Cell Lymphoma
Authors: Natalia G. Chernova, Yulia E. Vinogradova, Eugene E. Zvonkov, Yulia V. Sidorova, Alla Kovrigina, Alla Kovrigina, Elena N. Parovichnikova, Elena N. Parovichnikova, Valeri G. Savchenko
Journal: Blood (2016)
DECISION MAKING USING FRACTIONAL FLOW RESERVE IS ASSOCIATED WITH LOWER RATES OF INCOMPLETE REVASCULARIZATION COMPARED WITH ANGIOGRAPHIC GUIDED DECISION MAKING AMONGST PATIENTS WITH NSTEMI
Authors: Jamie John Layland, Jaclyn Carberry, Vanessa T.Y. May, Matthew Lee, Hany Eteiba, Mitchell Lindsay, Mark Petrie, Margaret McEntegart, Stuart Watkins, Aadil Shaukat, Keith Oldroyd, Nick Curzen, Arvind Sood, Kanarath Balachandran, Rajiv Das, Shahid Junejo, Andrew Hannah, Andrew Stewart, Robert Henderson, Alex McConnachie, Colin Berry
Journal: Journal of the American College of Cardiology (2017)
USE OF DIASTOLIC PARAMETERS ON TRANSTHORACIC ECHOCARDIOGRAM TO PREDICT LEFT ATRIAL APPENDAGE THROMBUS IN PATIENTS WITH ATRIAL FIBRILLATION
Authors: Michael Seth Garshick, Jennifer Mulliken, Matthew Schoenfeld, Katherine Riedy, Yu Guo, Judy Zhong, John A. Dodson, Muhamed Saric, Adam Skolnick
Journal: Journal of the American College of Cardiology (2017)
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
Authors: Jelena P Seferovic, Brian Claggett, Sara B Seidelmann, Ellen W Seely, Milton Packer, Michael R Zile, Jean L Rouleau, Karl Swedberg, Martin Lefkowitz, Victor C Shi, Akshay S Desai, John J V McMurray, Scott D Solomon
Journal: The Lancet Diabetes & Endocrinology (2017)
RISK OF STROKE IN ADULT PATIENTS WITH CONGENITAL HEART DISEASE COMPARED WITH THE GENERAL POPULATION: A DANISH NATIONWIDE POPULATION-BASED COHORT STUDY
Authors: Mette Glavind Bülow Pedersen, Morten Olsen, Morten Schmidt, Henning B. Laursen, Søren Johnsen, Nicolas Madsen
Journal: Journal of the American College of Cardiology (2017)
Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831.
Authors: Keith L. Knutson, Edith A. Perez, Karla V. Ballman, Courtney L. Erskine, Nicholas Fox, Christie-Ann McCarl, Nadine Norton, Susan V. Sumrall, Donald W. Northfelt, Winston Tan, Carmen Julia Calfa, Mark D. Pegram, Raphael Clynes
Journal: Journal of Clinical Oncology (2013)

522 Background: In the adjuvant setting, patients with HER2 breast cancer treated with trastuzumab and chemotherapy have superior survival compared to patients treated with chemotherapy alone. We previously showed that trastuzumab and chemotherapy induces HER2-specific antibodies which correlate with response to therapy in patients with HER2+ metastatic breast cancer. It remained unclear from those studies, however, whether the HER2-specific immunity played a role and if antibody immunity was associated with improved disease free survival in the adjuvant setting. In the present study, we addressed these questions by analyzing sera samples from a subset of patients enrolled in the NCCTG adjuvant trial, N9831, which includes an arm (Arm A) in which trastuzumab was not used. Arms B and C received trastuzumab sequentially or concurrently to chemotherapy, respectively. Methods: Pre-and post-treatment initiation sera were obtained from 50 women enrolled in N9831 (22 Arm A; 14 Arm B, and 14 Arm C). Lambda IgG antibodies (to avoid detection of trastuzumab) to HER2 were measured and presented as an index (&gt;0.2 was considered a positive response). Results: Prior to therapy, across all three arms, N9831 patients had similar mean HER2 IgG levels (0.19 units in Arm A, 0.14 in Arm B, and 0.23 in Arm C, P=0.85). Following treatment, the mean levels of antibodies increased in Arm B to 0.35 units and in Arm C to 0.56 units and were higher (p&lt;0.001) than in Arm A where levels did not increase. The proportion of patients who demonstrated antibody immunity increased by 9% in Arm A, 50% in Arm B and 28% in Arm C (P=0.026). Although the event rate was low in this cohort, Cox modeling suggested that larger increases in antibodies were associated with improved disease free survival (HR=0.23; p=0.04). Conclusions: These results show that the increased antibody immunity observed in adjuvant patients treated with combination trastuzumab and chemotherapy is clinically significant and results from the inclusion of trastuzumab. The findings may have important implications for improving treatment outcomes in patients treated with trastuzumab.
PREVALENCE AND CLINICAL SIGNIFICANCE OF ELECTROCARDIOGRAPHIC ABNORMALITIES IN GENERAL POPULATION OLDER THAN FORTY YEARS
Authors: Paula Awamleh, Rosa Maria Jimenez, Jose Maria Serrano Antolin, Alejandro Curcio, Juan Jose Gomez-Doblas, Javier Muniz, Joaquin Alonso, Eulalia Roig, Catherine Graupner, Pedro Talavera, Carmen Cristobal
Journal: Journal of the American College of Cardiology (2017)
Recipient Glycemic Micro-environments Govern Therapeutic Effects of Mesenchymal Stem Cell Infusion on Osteopenia
Authors: Bing-Dong Sui, Cheng-Hu Hu, Chen-Xi Zheng, Yi Shuai, Xiao-Ning He, Ping-Ping Gao, Pan Zhao, Meng Li, Xin-Yi Zhang, Tao He, Kun Xuan, Yan Jin
Journal: Theranostics (2017)

Therapeutic effects of mesenchymal stem cell (MSC) infusion have been revealed in various human disorders, but impacts of diseased micro-environments are only beginning to be noticed. Donor diabetic hyperglycemia is reported to impair therapeutic efficacy of stem cells. However, whether recipient diabetic condition also affects MSC-mediated therapy is unknown. We and others have previously shown that MSC infusion could cure osteopenia, particularly in ovariectomized (OVX) mice. Here, we discovered impaired MSC therapeutic effects on osteopenia in recipient type 1 diabetes (T1D). Through intensive glycemic control by daily insulin treatments, therapeutic effects of MSCs on osteopenia were maintained. Interestingly, by only transiently restoration of recipient euglycemia using single insulin injection, MSC infusion could also rescue T1D-induced osteopenia. Conversely, under recipient hyperglycemia induced by glucose injection in OVX mice, MSC-mediated therapeutic effects on osteopenia were diminished. Mechanistically, recipient hyperglycemic micro-environments reduce anti-inflammatory capacity of MSCs in osteoporotic therapy through suppressing MSC interaction with T cells via the Adenosine monophosphate-activated protein kinase (AMPK) pathway. We further revealed in diabetic micro-environments, double infusion of MSCs ameliorated osteopenia by anti-inflammation, attributed to the first transplanted MSCs which normalized the recipient glucose homeostasis. Collectively, our findings uncover a previously unrecognized role of recipient glycemic conditions controlling MSC-mediated therapy, and unravel that fulfillment of potent therapeutic effects of MSCs requires tight control of recipient micro-environments.
NORMALIZING PLATELET REACTIVITY OF CARDIOVASCULAR PATIENTS ON TICAGRELOR THERAPY USING FRESH PLATELETS: EX VIVO TESTING OF THE FUNCTIONAL RECOVERY ATTAINED WITHIN 48-HOURS OF STOPPING TREATMENT
Authors: Mohammad Urooj Zafar, Kevin Chen, Juan Rey-Mendoza, Carlos Linares Koloffon, Gustavo Jimenez, Gines Escolar, Valentin Fuster, Juan Badimon
Journal: Journal of the American College of Cardiology (2017)
EVALUATION OF A NEW RADIATION PROTECTION TECHNOLOGY (CARDIO-TRAP®) IN TRANSRADIAL PERCUTANEOUS CORONARY INTERVENTION PROCEDURES
Authors: Parth Parikh, Apurva Patel, Parloop Bhatt, Milan Chag, Roosha Parikh, Anish Chandarana, Hemang Baxi, Satya Gupta, Vipul Kapoor, Vineet Sankhla, Keyur Parikh
Journal: Journal of the American College of Cardiology (2017)
AN UPDATED COMPREHENSIVE META-ANALYSIS COMPARING DRUG-ELUTING STENTS WITH BARE METAL STENTS IN SAPHENOUS VEIN GRAFT INTERVENTIONS
Authors: Rahman Shah, Muhammad Shahreyar, Abdul Rashid, Mohamed Morsy, Inyong Hwang, Beatrix Ramos Bondy, Mark Heckle
Journal: Journal of the American College of Cardiology (2017)
포스터발표 : HBsAg 양성 간경변증 환자에서 간세포암종 발생의 위험인자에 대한 환자 대조군 연구 -음주를 중심으로-
Authors: 원형식, 권오상, 한우진, 이서영, 조문숙, 김상균, 김영석, 이정일, 이진우, 김영수, 천병철, 김연수, 김주현
Journal: Clinical and Molecular Hepatology (2009)
THE IMPACT OF RECANALIZATION OF CHRONIC TOTAL OCCULUDED CORONARY ARTERY ON ELECTROPHYSIOLOGICAL SUBSTRATE OF LEFT VENTRICLE
Authors: Kennosuke Yamashita, Masahiko Ochiai, Yuji Oyama, Wataru Igawa, Morio Ono, Takehiko Kido, Seitarou Ebara, Toshitaka Okabe, Myong Hwa Yamamoto, Shigeo Saito, Kisaki Amemiya, Naoei Isomura, Hiroshi Araki
Journal: Journal of the American College of Cardiology (2017)
Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
Authors: Leon A Adams, Quentin M Anstee, Herbert Tilg, Giovanni Targher
Journal: Gut (2017)

Key physiological functions of the liver, including glucose and lipid metabolism, become disturbed in the setting of non-alcoholic fatty liver disease (NAFLD) and may be associated with a systemic inflammatory '<i>milieu</i>' initiated in part by liver-secreted cytokines and molecules. Consequently, the pathophysiological effects of NAFLD extend beyond the liver with a large body of clinical evidence demonstrating NAFLD to be independently associated with both prevalent and incident cardiovascular disease (CVD), chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). The magnitude of risk of developing these extrahepatic diseases parallels the underlying severity of NAFLD, such that patients with non-alcoholic steatohepatitis (NASH) appear to be at greater risk of incident CVD, CKD and T2DM than those with simple steatosis. Other modifiers of risk may include genetic variants (eg, patatin-like phospholipase domain-containing 3 and trans-membrane 6 superfamily member 2 polymorphisms), visceral adipose tissue accumulation, dietary intake and the gut microbiome. Emerging data also suggest that NAFLD may be a risk factor for colonic neoplasia and reduced bone mineral density, especially among men. Importantly, improvement/resolution of NAFLD is associated with a reduced incidence of T2DM and improved kidney function, adding weight to causality and suggesting liver focused treatments may reduce risk of extrahepatic complications. Awareness of these associations is important for the clinicians such that CVD risk factor management, screening for T2DM and CKD are part of the routine management of patients with NAFLD.
Exome Array Analyses Identify Low-Frequency Germline Variants Associated with Increased Risk of AML in a HLA-Matched Unrelated Donor Blood and Marrow Transplant Population
Authors: Alyssa I. Clay, Theresa Hahn, Qianqian Zhu, Li Yan, Leah Preus, Daniel O. Stram, Christopher A. Haiman, Loreall C. Pooler, Xin Sheng, Kenan Onel, Qian Liu, Qiang Hu, Song Liu, Xiaochun Zhu, Stephen R. Spellman, Marcelo C. Pasquini, Philip L. McCarthy, Lara E. Sucheston-Campbell
Journal: Blood (2016)
FIRST MEDICAL CONTACT TO DEVICE TIME IN STEMI PATIENTS PRESENTING WITH CARDIOGENIC SHOCK: INSIGHTS FROM MISSION, A LIFELINE STEMI SYSTEMS ACCELERATOR
Authors: Ajar Kochar, Hussein Al-Khalidi, Steen Hansen, Jay Shavadia, Mayme Roettig, Christopher Fordyce, James Jollis, Christopher Granger
Journal: Journal of the American College of Cardiology (2017)
IMPACT OF MULTIDISCIPLINARY HEART FAILURE TRANSITIONAL CARE INTERVENTIONS ON DISPARITIES IN 30-DAY READMISSION RATES
Authors: Victor Valencia, Preeti Kansal, Hannah Alphs Jackson, Robin Fortman, Amanda Vlcek, Allen Anderson, Charles Davidson, Nicholas Soulakis, Clyde Yancy, Raja Mutharasan
Journal: Journal of the American College of Cardiology (2017)
Evaluation of Bone Marrow Reticulin in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Treated with Eltrombopag – Data From the EXTEND Study
Authors: Russell K. Brynes, Attilio Orazi, Shalini Verma, Andres Brainsky, Christine K Bailey, Kalpana Bakshi
Journal: Blood (2011)
Clinical differences among Hispanics and non-Hispanic whites with colorectal cancer: A single institution’s experience over 20 years.
Authors: Andrew Jennis, Narjust Duma, Larysa Jessica Sanchez, Yulanka Castro, Donald A. McCain, Zubin M. Bamboat, Martin Gutierrez
Journal: Journal of Clinical Oncology (2015)

e14512 Background: Hispanics (H) are the largest and fastest growing ethnic group in the US. With most of the studies focusing in African Americans and Non-Hispanics whites (NHW), defining the characteristics of colorectal cancer (CRC) in the Hispanic population has been a challenge. The aim of our study was to compare the clinico-pathological characteristics and survival among H and NHW with CRC. Methods: We reviewed the records of all patients (pts) diagnosed with CRC at our institution from 1993 to 2013. A total of 2146 pts were studied. Demographics, tumor characteristics, and survival were analyzed. Kaplan-Meier and Cox regression were used for survival and multivariate analysis. Results: There were 318 H and 1828 NHW. Median age at diagnosis was 63 years in H and 70 years in NHW. A significant difference was found in the stage IV pts, with a median age of 60 years for H and 71 years for NHW. Adenocarcinoma was the most common histologic subtype for both groups. At diagnosis, 96 (30%) of H had stage IV disease compared with 324 (18%) of NHW (p < 0.0001). H were more likely to have left side and poorly differentiated tumors compared to NHW (71% vs. 63%, p < 0.008; 24% vs 10%, p < 0.0001, respectively). H had a higher recurrence rate than NHW (13% vs 4%, p < 0.0001). There was a significant difference in median overall survival (all stages) between the two groups, being 76 mo for H (95% CI: 69-83) and 180 mo for NHW (95%CI: 112-251), p < 0.0001. Hispanic ethnicity (OR: 1.64, p < 0.009), married status (OR: 0.68, p < 0.0001), histologic grade (OR: 1.21, p < 0.003) and negative margins after resection (OR: 0.41, p < 0.0001) were independent predictors of survival by multivariate analysis. Tumor location was predictor of survival in univariate analysis. CRC was the primary cause of death in 23% of H vs. 12% of NHW (p < 0.0001). Conclusions: In our cohort, Hispanic pts were diagnosed with CRC at a younger age, were more likely to have left side and poorly differentiated tumors, to present with advanced disease at diagnosis, and had shorter overall survival when compared to NHW. Further research should aim to elucidate the basis of these differences, as this could potentially impact screening and management in the Hispanic population.
Targeted Whole Exome Sequencing of 87 Predisposition Genes in 156 Patients from the Oresund Region with Bleeding Disorders
Authors: Eva B Leinoe, Eva Zetterberg, Olga Oestrup, Peter Kampmann, Norstrom Eva, Nadine G Andersson, Savvas Kinalis, Klaus Qvortrup, Caroline Maria Rossing
Journal: Blood (2016)
LOW LDL-CHOLESTEROL TARGET VALUE ATTAINMENT AT THE TIME OF ACUTE CORONARY SYNDROME (ACS) AND EVEN 4 MONTHS AFTER THE ACUTE EVENT DUE TO LACK OF ADJUSTMENT IN LIPID LOWERING TREATMENT: RESULTS FROM THE DYSLIPIDEMIA INTERNATIONAL STUDY II ACS
Authors: Anselm K. Gitt, Dominik Lautsch, Martin Horack, Philippe Brudi, Larry Liu, Gaetano De Ferrari, Kian Keong Poh, Jean Ferrières
Journal: Journal of the American College of Cardiology (2017)
Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib
Authors: Cecelia R. Miller, Amy S. Ruppert, Nyla A. Heerema, Kami J. Maddocks, Jadwiga Labanowska, Heather Breidenbach, Gerard Lozanski, Weiqiang Zhao, Amber Gordon, Jeffrey Jones, Joseph M. Flynn, Samantha Jaglowski, Leslie A. Andritsos, Farrukh T. Awan, Kristie A. Blum, Michael R. Grever, Amy J. Johnson, Lynne V. Abruzzo, Erin K. Hertlein, Jennifer A. Woyach, John C. Byrd
Journal: Blood (2016)
Bone Marrow Adipocyte-Derived Free Fatty Acids Induce Gene Signature Linking Transcription with Metabolic Changes That Contribute to Survival of Acute Monocytic Leukemia Cells
Authors: Yoko Tabe, Masako Harada, Yuka Miyamae, Kaoru Mogushi, Saiko Kazuno, Tsutomu Fujimura, Hiromichi Matsushita, Takashi Ueno, Takehiko Yokomizo, Takashi Miida, Ismael Samudio, Michael Andreeff, Marina Konopleva
Journal: Blood (2014)